But do they actually solve the underlying problem?
The answer is: Not really.
Statins: Lower LDL, But Not Without Risks
Statins work by blocking cholesterol production in the liver, which leads to lower LDL (“bad”) cholesterol levels.
While statins can lower numbers on a blood test, they do not address why cholesterol became elevated in the first place — often related to poor diet, inflammation, metabolic dysfunction, and insulin resistance.
Moreover, statins:
- Can deplete essential nutrients like CoQ10
- May cause muscle damage and fatigue [1]
- Do not necessarily improve overall mortality for everyone, especially in low-risk populations [2]
In other words, they manage a symptom — not the root cause.
Ozempic: May help for Blood Sugar, Limited for Cholesterol
Ozempic, a GLP-1 receptor agonist, is primarily used to treat type 2 diabetes and support weight loss. It can modestly lower cholesterol indirectly by improving insulin sensitivity and helping with weight loss.
However, Ozempic:
- Is not a cholesterol medication
- May slightly reduce triglycerides and LDL, but not enough to replace proper cardiovascular care [3]
- Works only as long as you stay on it
Again, it doesn’t correct the lifestyle and metabolic imbalances that drive cholesterol problems in the first place.
The Real Solution: Fix the Foundation
Neither statins nor Ozempic offer a true cure for unhealthy cholesterol patterns. Real, lasting improvement comes from:
- Anti-inflammatory nutrition (rich in fiber, antioxidants, and healthy fats)
- Exercise to improve blood lipid profiles naturally
- Weight management and blood sugar control through sustainable habits
- Targeted nutrients found in LipiBalance
References
- Thompson PD, et al. “Statin-associated side effects.” J Am Coll Cardiol. 2016;67(20):2395-2410.
- Diamond DM, Ravnskov U. “How statistical deception created the appearance that statins are safe and effective.” Expert Rev Clin Pharmacol. 2015;8(2):201-210.
- Davies MJ, et al. “Effects of once-weekly semaglutide on cardiovascular risk factors in subjects with type 2 diabetes.” Diabetes Obes Metab. 2017;19(7):951-959.